Wuhan Yingnashi Pharmaceutical

Wuhan Innace Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Wuhan, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in metabolic diseases, autoimmune disorders, and oncology. Its lead clinical program, INS001, is a highly potent and selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Additionally, the company is advancing a pipeline that includes a THR-beta agonist for non-alcoholic steatohepatitis (NASH) and selective kinase inhibitors for inflammatory conditions. Innace leverages its proprietary drug discovery platform to optimize the safety and efficacy profiles of its candidates, aiming to deliver best-in-class treatments to global markets.